Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
01 2019
Historique:
received: 09 07 2018
accepted: 06 12 2018
entrez: 13 2 2019
pubmed: 13 2 2019
medline: 22 4 2020
Statut: epublish

Résumé

Although botulinum neurotoxin serotype A (BoNT/A) products are common treatments for various disorders, there is only one commercial BoNT/B product, whose low potency, likely stemming from low affinity toward its human receptor synaptotagmin 2 (hSyt2), has limited its therapeutic usefulness. We express and characterize two full-length recombinant BoNT/B1 proteins containing designed mutations E1191M/S1199Y (rBoNT/B1

Identifiants

pubmed: 30746458
doi: 10.1126/sciadv.aau7196
pii: aau7196
pmc: PMC6357751
doi:

Substances chimiques

Recombinant Proteins 0
SYT2 protein, human 0
Synaptotagmin II 0
rimabotulinumtoxinB 0Y70779M1F
Botulinum Toxins, Type A EC 3.4.24.69
Glycine TE7660XO1C

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

eaau7196

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK034854
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI132387
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS080833
Pays : United States

Références

Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
pubmed: 15299374
Toxicon. 2008 Sep 1;52(3):455-64
pubmed: 18639570
Biosci Rep. 2013 Nov 05;33(6):
pubmed: 23968392
Pharmacotherapy. 2013 Mar;33(3):304-18
pubmed: 23400888
Neuroscience. 1994 Dec;63(3):837-50
pubmed: 7534885
Toxicon. 2015 Dec 1;107(Pt A):77-84
pubmed: 26260691
Basic Clin Pharmacol Toxicol. 2015 Jun;116(6):524-8
pubmed: 25395371
Nat Commun. 2017 Jul 3;8(1):53
pubmed: 28674381
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67
pubmed: 21460454
Acta Crystallogr D Biol Crystallogr. 2006 Jan;62(Pt 1):72-82
pubmed: 16369096
Toxicon. 2001 Dec;39(12):1815-20
pubmed: 11600142
BMC Urol. 2014 May 15;14:37
pubmed: 24885301
PLoS Pathog. 2014 Jul 10;10(7):e1004177
pubmed: 25010769
Nature. 2006 Dec 21;444(7122):1092-5
pubmed: 17167421
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Hum Mol Genet. 2016 Nov 1;25(21):4703-4716
pubmed: 28173138
FEBS Lett. 2012 Feb 17;586(4):310-3
pubmed: 22265973
J Cell Sci. 2012 Jul 1;125(Pt 13):3233-42
pubmed: 22454523
Pharmacol Res Perspect. 2017 Jan 31;5(1):e00289
pubmed: 28596838
Toxicon. 2013 Sep;71:18-24
pubmed: 23707612
J Biol Chem. 1994 Apr 8;269(14):10498-503
pubmed: 8144634
PLoS One. 2017 Oct 5;12(10):e0185628
pubmed: 28982136
Neurology. 2005 Nov 8;65(9):1423-9
pubmed: 16275831
Nat Commun. 2013;4:2058
pubmed: 23807078
Toxicology. 2013 Jun 7;308:50-9
pubmed: 23567313
BMC Med Genomics. 2009 Jul 14;2:44
pubmed: 19602279
J Neurosci. 2006 Dec 27;26(52):13493-504
pubmed: 17192432
Nat Struct Biol. 2000 Aug;7(8):693-9
pubmed: 10932256
Tremor Other Hyperkinet Mov (N Y). 2012;2:
pubmed: 23440162
Nature. 1992 Oct 29;359(6398):832-5
pubmed: 1331807
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
J Cell Biol. 2003 Sep 29;162(7):1293-303
pubmed: 14504267
Muscle Nerve. 2004 May;29(5):615-27
pubmed: 15116365
EMBO J. 2006 May 17;25(10):2039-50
pubmed: 16642042
Neurology. 1997 Jul;49(1):189-94
pubmed: 9222189
Toxicol Sci. 2012 Apr;126(2):426-35
pubmed: 22223483
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):271-81
pubmed: 21460445
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Toxins (Basel). 2012 Oct;4(10):913-39
pubmed: 23162705
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204-14
pubmed: 23793146
Curr Opin Microbiol. 2012 Jun;15(3):325-36
pubmed: 22770659
Mov Disord. 2013 Nov;28(13):1775-83
pubmed: 23868503
Clin Neuropharmacol. 2009 Jul-Aug;32(4):213-8
pubmed: 19620852
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840

Auteurs

Mark Elliott (M)

Ipsen Bioinnovation, 102 Park Drive, Milton Park, Abingdon OX14 4RY, UK.

Christine Favre-Guilmard (C)

Ipsen Innovation, 5 Avenue du Canada, 91940 Les Ulis, France.

Sai Man Liu (SM)

Ipsen Bioinnovation, 102 Park Drive, Milton Park, Abingdon OX14 4RY, UK.

Jacquie Maignel (J)

Ipsen Innovation, 5 Avenue du Canada, 91940 Les Ulis, France.

Geoffrey Masuyer (G)

Department of Biochemistry and Biophysics, Stockholm University, Stockholm SE-106 91, Sweden.

Matthew Beard (M)

Ipsen Bioinnovation, 102 Park Drive, Milton Park, Abingdon OX14 4RY, UK.

Christopher Boone (C)

Department of Urology, Boston Children's Hospital, Department of Microbiology and Immunobiology and Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.

Denis Carré (D)

Ipsen Innovation, 5 Avenue du Canada, 91940 Les Ulis, France.

Mikhail Kalinichev (M)

Ipsen Innovation, 5 Avenue du Canada, 91940 Les Ulis, France.

Stephane Lezmi (S)

Ipsen Innovation, 5 Avenue du Canada, 91940 Les Ulis, France.

Imran Mir (I)

Ipsen Bioinnovation, 102 Park Drive, Milton Park, Abingdon OX14 4RY, UK.

Camille Nicoleau (C)

Ipsen Innovation, 5 Avenue du Canada, 91940 Les Ulis, France.

Shilpa Palan (S)

Ipsen Bioinnovation, 102 Park Drive, Milton Park, Abingdon OX14 4RY, UK.

Cindy Perier (C)

Ipsen Innovation, 5 Avenue du Canada, 91940 Les Ulis, France.

Elsa Raban (E)

Ipsen Innovation, 5 Avenue du Canada, 91940 Les Ulis, France.

Sicai Zhang (S)

Department of Urology, Boston Children's Hospital, Department of Microbiology and Immunobiology and Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.

Min Dong (M)

Department of Urology, Boston Children's Hospital, Department of Microbiology and Immunobiology and Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.

Pål Stenmark (P)

Department of Biochemistry and Biophysics, Stockholm University, Stockholm SE-106 91, Sweden.
Department of Experimental Medical Science, Lund University, 221 00 Lund, Sweden.

Johannes Krupp (J)

Ipsen Bioinnovation, 102 Park Drive, Milton Park, Abingdon OX14 4RY, UK.
Ipsen Innovation, 5 Avenue du Canada, 91940 Les Ulis, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH